United States (US) Parkinsons Disease Therapeutics Market (2025-2031) | Competitive Landscape, Share, Size & Revenue, Value, Segmentation, Forecast, Outlook, Growth, Analysis, Trends, Companies, Industry

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3.1 United States (US) Country Macro Economic Indicators

3.2 United States (US) Parkinsons Disease Therapeutics Market Revenues & Volume, 2021 & 2031F

3.3 United States (US) Parkinsons Disease Therapeutics Market - Industry Life Cycle

3.4 United States (US) Parkinsons Disease Therapeutics Market - Porter's Five Forces

3.5 United States (US) Parkinsons Disease Therapeutics Market Revenues & Volume Share, By Drug Class, 2021 & 2031F

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing prevalence of Parkinson's disease in the United States

4.2.2 Technological advancements in the development of Parkinson's disease therapeutics

4.2.3 Rising healthcare expenditure and investments in research and development for Parkinson's disease treatments

4.3 Market Restraints

4.3.1 Stringent regulatory requirements for drug approval in the United States

4.3.2 High cost associated with Parkinson's disease therapeutics

4.3.3 Adverse side effects and limited efficacy of current treatment options

6.1 United States (US) Parkinsons Disease Therapeutics Market, By Drug Class

6.1.1 Overview and Analysis

6.1.2 United States (US) Parkinsons Disease Therapeutics Market Revenues & Volume, By Drug Class, 2021- 2031F

6.1.3 United States (US) Parkinsons Disease Therapeutics Market Revenues & Volume, By Levodopa Combination, 2021- 2031F

6.1.4 United States (US) Parkinsons Disease Therapeutics Market Revenues & Volume, By Dopamine Agonists, 2021- 2031F

6.1.5 United States (US) Parkinsons Disease Therapeutics Market Revenues & Volume, By MAO-B Inhibitors, 2021- 2031F

6.1.6 United States (US) Parkinsons Disease Therapeutics Market Revenues & Volume, By COMT Inhibitors, 2021- 2031F

7.1 United States (US) Parkinsons Disease Therapeutics Market Export to Major Countries

7.2 United States (US) Parkinsons Disease Therapeutics Market Imports from Major Countries

8.1 Patient adherence rate to prescribed Parkinson's disease therapeutics

8.2 Average time taken for regulatory approval of new Parkinson's disease drugs

8.3 Number of clinical trials for innovative Parkinson's disease treatments initiated in the United States

9.1 United States (US) Parkinsons Disease Therapeutics Market Opportunity Assessment, By Drug Class, 2021 & 2031F

10.1 United States (US) Parkinsons Disease Therapeutics Market Revenue Share, By Companies, 2024

10.2 United States (US) Parkinsons Disease Therapeutics Market Competitive Benchmarking, By Operating and Technical Parameters